Novo Nordisk: beats consensus and raises guidance.
(CercleFinance.com) - Novo Nordisk shares were reacting positively to the Danish healthcare company beating the consensus in second-quarter, in addition to upgrading its full-year guidance.
Group second-quarter sales increased by 4% in Danish kroner and are up 3% in local currency to 57.1 billion kroner, driven by new products for diabetes and obesity care.
Its net profit increased by 4% to 20.1 billion Danish kroner.
The financial outlook for 2017 has been updated and sales growth, measured in local currency, is now expected to be in a range of 1% to 3% compared with the previous range of 0% to 3%.
After operating profit grew by 6% over the past quarter, growth measured in local currency is now expected to be in a range of 1% to 5% this year compared with the previous range of -1% to 3%.
The shares were up 5.7% at 277 Danish kroner after these numbers were released.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
Group second-quarter sales increased by 4% in Danish kroner and are up 3% in local currency to 57.1 billion kroner, driven by new products for diabetes and obesity care.
Its net profit increased by 4% to 20.1 billion Danish kroner.
The financial outlook for 2017 has been updated and sales growth, measured in local currency, is now expected to be in a range of 1% to 3% compared with the previous range of 0% to 3%.
After operating profit grew by 6% over the past quarter, growth measured in local currency is now expected to be in a range of 1% to 5% this year compared with the previous range of -1% to 3%.
The shares were up 5.7% at 277 Danish kroner after these numbers were released.
Copyright (c) 2017 CercleFinance.com. All rights reserved.